MeSH Review:
Vomiting
- Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Amitai, Y., Yeung, A.C., Moye, J., Lovejoy, F.H. Ann. Intern. Med. (1986)
- Optimizing metoclopramide control of cisplatin-induced emesis. Meyer, B.R., Lewin, M., Drayer, D.E., Pasmantier, M., Lonski, L., Reidenberg, M.M. Ann. Intern. Med. (1984)
- Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. Gandara, D.R., Nahhas, W.A., Adelson, M.D., Lichtman, S.M., Podczaski, E.S., Yanovich, S., Homesley, H.D., Braly, P., Ritch, P.S., Weisberg, S.R. J. Clin. Oncol. (1995)
- Hyponatremic encephalopathy: is central pontine myelinolysis a component? Tien, R., Arieff, A.I., Kucharczyk, W., Wasik, A., Kucharczyk, J. Am. J. Med. (1992)
- PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Sanz, M.J., Cortijo, J., Morcillo, E.J. Pharmacol. Ther. (2005)
- Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Angrist, B., Rotrosen, J., Gershon, S. Psychopharmacology (Berl.) (1980)
- Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. Parkes, J.D., Debono, A.G., Marsden, C.D. J. Neurol. Neurosurg. Psychiatr. (1976)
- Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. Relling, M.V., Mulhern, R.K., Fairclough, D., Baker, D., Pui, C.H. J. Pediatr. (1993)
- Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret. Lau, A.H., Ngan, M.P., Rudd, J.A., Yew, D.T. Eur. J. Pharmacol. (2005)
- Symptomatic low intracranial pressure in shunted hydrocephalus. Foltz, E.L., Blanks, J.P. J. Neurosurg. (1988)
- Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist. Roila, F., Ballatori, E., Del Favero, A. N. Engl. J. Med. (1999)
- Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. Navari, R.M., Reinhardt, R.R., Gralla, R.J., Kris, M.G., Hesketh, P.J., Khojasteh, A., Kindler, H., Grote, T.H., Pendergrass, K., Grunberg, S.M., Carides, A.D., Gertz, B.J. N. Engl. J. Med. (1999)
- Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. Marty, M., Pouillart, P., Scholl, S., Droz, J.P., Azab, M., Brion, N., Pujade-Lauraine, E., Paule, B., Paes, D., Bons, J. N. Engl. J. Med. (1990)
- Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. Gralla, R.J., Itri, L.M., Pisko, S.E., Squillante, A.E., Kelsen, D.P., Braun, D.W., Bordin, L.A., Braun, T.J., Young, C.W. N. Engl. J. Med. (1981)
- Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Loprinzi, C.L., Ellison, N.M., Schaid, D.J., Krook, J.E., Athmann, L.M., Dose, A.M., Mailliard, J.A., Johnson, P.S., Ebbert, L.P., Geeraerts, L.H. J. Natl. Cancer Inst. (1990)
- Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Van Sickle, M.D., Oland, L.D., Ho, W., Hillard, C.J., Mackie, K., Davison, J.S., Sharkey, K.A. Gastroenterology (2001)
- PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Banner, K.H., Trevethick, M.A. Trends Pharmacol. Sci. (2004)
- Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Hu, D.L., Zhu, G., Mori, F., Omoe, K., Okada, M., Wakabayashi, K., Kaneko, S., Shinagawa, K., Nakane, A. Cell. Microbiol. (2007)
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., Glick, J. J. Clin. Oncol. (1996)
- Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.B., Possinger, K., Roots, I., Brockmöller, J. J. Clin. Oncol. (2002)
- Effects of cholinoceptor and 5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. Qin, X.Y., Pilot, M.A., Thompson, H., Scott, M. Br. J. Pharmacol. (1993)
- The action of dazopride to enhance gastric emptying and block emesis. Costall, B., Domeney, A.M., Gunning, S.J., Kelly, M.E., Naylor, R.J., Nohria, V., Owera-Atepo, J.B., Simpson, K.M., Tan, C.C., Tattersall, D. Neuropharmacology (1987)
- 5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930. Waeber, C., Hoyer, D., Palacios, J.M. Neuroscience (1989)
- A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Thibault, A., Cooper, M.R., Figg, W.D., Venzon, D.J., Sartor, A.O., Tompkins, A.C., Weinberger, M.S., Headlee, D.J., McCall, N.A., Samid, D. Cancer Res. (1994)
- Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Hovde, C.J., Marr, J.C., Hoffmann, M.L., Hackett, S.P., Chi, Y.I., Crum, K.K., Stevens, D.L., Stauffacher, C.V., Bohach, G.A. Mol. Microbiol. (1994)
- Neurobiology of substance P and the NK1 receptor. Mantyh, P.W. The Journal of clinical psychiatry. (2002)
- Noradrenaline-induced emesis. Alpha-2 adrenoceptor mediation in the area postrema. Beleslin, D.B., Strbac, M. Neuropharmacology (1987)
- The effects of dopexamine on the cardiovascular system of the dog. Brown, R.A., Farmer, J.B., Hall, J.C., Humphries, R.G., O'Connor, S.E., Smith, G.W. Br. J. Pharmacol. (1985)
- Identification and characterization of the emetic effects of peptide YY. Harding, R.K., McDonald, T.J. Peptides (1989)
- Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth, B.J. Lancet (2005)
- Neurohypophyseal secretion in response to cholecystokinin but not meal-induced gastric distention in humans. Miaskiewicz, S.L., Stricker, E.M., Verbalis, J.G. J. Clin. Endocrinol. Metab. (1989)
- Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Kaiser, R., Tremblay, P.B., Sezer, O., Possinger, K., Roots, I., Brockmöller, J. Pharmacogenetics (2004)
- Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Rupniak, N.M., Kramer, M.S. Trends Pharmacol. Sci. (1999)
- Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. McDermed, J.E., Cohen, J.L., Joseph, C., Strum, S.B. J. Clin. Oncol. (1985)
- A model for carbamate and organophosphate-induced emesis in humans. D'Mello, G.D., Sidell, F.R. Neuroscience and biobehavioral reviews. (1991)